Investors

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient´s dendritic cells to activate an immune response specific to the patient´s disease. Argos´ most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV.


Stock Quote

OT: ARGS
0.21
- 0.08 (-27.59%)

Day High:
0.30

Day Low:
0.21

Volume:
670,135

3:59 PM ET on Apr 26, 2018
Delayed at least 20 minutes.